Phytochemicals as modulators of β-cells and immunity for the therapy of type 1 diabetes: Recent discoveries in pharmacological mechanisms and clinical potential

Maria Karmella Apaya; Tien-Fen Kuo; Meng-Ting Yang; Greta Yang; Chiao-Ling Hsiao; Song-Bin Chang; Yenshou Lin; Wen-Chin Yang

doi:10.1016/j.phrs.2020.104754

Phytochemicals as modulators of β-cells and immunity for the therapy of type 1 diabetes: Recent discoveries in pharmacological mechanisms and clinical potential

Journal

Pharmacological Research

Journal Volume

156

Start Page

104754

ISSN

1043-6618

Date Issued

2020-06

Author(s)

Maria Karmella Apaya

Tien-Fen Kuo

Meng-Ting Yang

Greta Yang

Chiao-Ling Hsiao

Song-Bin Chang

Yenshou Lin

Wen-Chin Yang

DOI

10.1016/j.phrs.2020.104754

URI

https://www.sciencedirect.com/science/article/pii/S1043661819328075?via%3Dihub

https://scholars.tari.gov.tw/handle/123456789/15559

Abstract

Type 1 diabetes (T1D) is a lethal autoimmune disease afflicting as many as 10 million people worldwide. Considerable advances have been made in early diagnosis and understanding the cause of T1D development. However, new remedies are still in great demand as TID remains an incurable disease. Natural products, primarily phytochemicals, are an extraordinary source of discovery of drug leads for diabetes. This review covers recent findings regarding plant compounds and extracts for T1D based on a literature search of articles published between 2004-2019 in PubMed, Reaxyx, and America/European patent databases. Over this period more than 90 plant compounds and extracts were reported to have beneficial effects on T1D via multiple mechanisms involving the regulation of immunity and/or beta cells. In this review, we focus on recent progress in the understanding of the chemistry (chemical structure and plant source), anti-diabetic bioactivities, and likely mechanisms of action of plant compounds for T1D. Mechanistic studies are summarized, which indicate that flavonoids, terpenoids, and anthranoids can inhibit starch-digesting enzymes, aldose reductase, MAP kinases, NF kappa B, and/or I kappa B kinases implicated in energy metabolism, beta-cells, and immunity. Furthermore, human clinical trials centering on flavonoids, isoflavonoids, terpenoids, stilbenoids, and polyynes are discussed, and an overview of emerging anti-diabetic strategies using plant compounds and extracts for applications in T1D prophylaxis and therapy is also provided.

Subjects

Type 1 diabetes

Phytochemicals

Mechanism of mode

Clinical application

SDGs

[SDGs]SDG3

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD

Type

review